Cell & Developmental Biology

Cell & Developmental Biology
Open Access

ISSN: 2168-9296

Abstract

Potential Use of miRNA-17-92, miRNA-221, and miRNA-96 as Theranostic Agents in Chronic Myeloid Leukemia (CML): A Systematic Review and Bioinformatic Analysis

Ajib Zaim Alamsyah*, Ngakan Ketut Wira Suastika, Bryan Gervais de Liyis, Kevin Nathaniel Cuandra

Introduction: There are many challenges in diagnosing and treating CML, including cryptic translocations that render chromosomes undetectable, high costs which can be up to 63.000 USD annually, limited technology, low complete hematologic response, side effects, and resistance. Therefore, developing more effective and efficient diagnostic and therapeutic methods is required. MicroRNA (miRNA/miR)-based gene silencing technology offers potential as a theranostic approach for managing gene expression-related diseases. This study aims to review the role of miRNA as a cutting-edge theranostic technology and its potential application in CML.

Methods: The PRISMA guidelines were applied to perform current systematic review pertaining to articles in the two databases. Inclusion and exclusion criteria were used to guide literature screening. A miRNA-mRNA pharmacology network was constructed to see whether there is a link between target genes between miRNAs using Cytoscape software.

Results and discussion: The pharmacology network results suggest a link between the mechanisms of action of these three miRNAs in CML, including VCAM1, MDM4, and other 529 genes. miRNA-17-92 and miRNA-221 showed increased expression in CML, while miRNA-96 showed decreased expression. miRNA-17-92 expression can be suppressed with anti-miRNA-72-92, targeting A20 and inactivating NF-kB signaling to promote apoptosis and inhibit CML cell proliferation. Additionally, anti-miRNA-221 can work by increasing p27Kip1 expression, which reduces vitality, inhibits proliferation, and prevents the G1-to-S phase transition of CML cells. Moreover, miRNA-96 mimics can be used to avoid CML cell transformation by degrading BCR-ABL1 targets and reducing the activity of the STAT5 and MEK/ERK signaling pathways. miRNA-17-92, miRNA-221, and miRNA-96 also enhance CML cells' sensitivity to imatinib.

Conclusion: miRNA-17-92, miRNA-221, and miRNA-96 show potential as diagnostic biomarkers, as well as potential therapy pathways for inducing apoptosis, reducing the vitality, proliferation, and survival of CML cells.

Published Date: 2026-09-24; Received Date: 2025-01-06

Top